Abstract
Tumor doubling time is an important clinical parameter, but it is rarely reported in cervical cancer. We encountered a case in which the tumor doubling time could be measured using a radiotherapy planning device. A woman in her 40s was diagnosed with cervical cancer stage IB1 (squamous cell carcinoma) and refused treatment. One year and five months later, definitive radiation therapy was administered. Magnetic resonance imaging was performed five times before the start of treatment. When the tumor volume was measured using the radiotherapy planning system - RayStation🄬 (RaySearch Laboratories, Stockholm, Sweden) on the T2 sagittal image, the tumor doubling time was 76 days, and the tumor volume had increased exponentially.
Highlights
Pathological characteristics of malignant tumors include the invasive growth and metastasis formation
In radiotherapy, the radiotherapy planning system (RPS) has been developed so that the tumor volume (TV) can be measured from various image modalities
We report a case of cervical cancer in which the doubling time (DT) was measured from magnetic resonance imaging (MRI) images using RayStation (RaySearch Laboratories, Stockholm, Sweden), a type of RPS
Summary
Pathological characteristics of malignant tumors include the invasive growth and metastasis formation. The growth rate related to the appearance over time is an important indicator of the characteristics of malignant tumors. We report a case of cervical cancer in which the DT was measured from MRI images using RayStation (RaySearch Laboratories, Stockholm, Sweden), a type of RPS. A woman in her 40s was diagnosed with cervical cancer stage IB1 (squamous cell carcinoma), but refused treatment. How to cite this article Kurosaki H, Utsumi N, Miura K (January 10, 2021) Radiotherapy Planning System to Measure Tumor Doubling Time in Cervical Cancer. Two radiation oncologists collaborated to contour the tumor using MRI T2 sagittal images. DT: tumor doubling time, SCC: squamous cell carcinoma antigen in the serum, CYFRA: cytokeratin 19 fragment in the serum. Tumor markers were normalized on the last day of radiation therapy (Day 562), and no mass was found on pelvic examination
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
